Table 2.
Characteristics of the cases used for preparing the brain lysates used as seeds with the respective seeding performance in relation to the presence/absence, loads and expansion of induced Aβ, AβN3pE and AβpSer8 deposition in mice
| Induced pathology in the treated mice | Characteristics of lysates | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cases and fraction | Antibody | Seeded Aβ speciesa | Total n per group | Average Aβ loadb | Average hAP scorec | Aβ content, ng/µl | Aβ phase | Braak NFT stage | Temp Aβ load | B-Aβ stage | B-Aβ plaque stage | B-Aβ lysate injected |
| Comparison among different fractions of lysates from an Alzheimer’s disease and a p-preAD case | ||||||||||||
| p-preAD2 soluble fraction | Aβ | 50.00 | 6 | 0.037 (0.063) | 13.9 (20.2) | 0.011 | 1 | 1 | 0 | 0 | 2 | 0 |
| AβN3PE | 0.00 | 0 (0) | 0 (0) | |||||||||
| AβpSer8 | 0.00 | 0 (0) | 0 (0) | |||||||||
| p-preAD2 dispersible fraction | Aβ | 50.00 | 6 | 0.021 (0.024) | 27.1 (19.7) | 0.009 | 1 | 1 | 0 | 0 | 2 | 0 |
| AβN3PE | 33.33 | 0.001 (0.001) | 8.3 (11.8) | |||||||||
| AβpSer8 | 0.00 | 0 (0) | 0 (0) | |||||||||
| p-preAD2 total supernatant fraction | Aβ | 50.00 | 6 | 0.023 (0.035) | 15 (22.4) | 0.007 | 1 | 1 | 0 | 0 | 2 | 0 |
| AβN3PE | 0.00 | 0 (0) | 0 (0) | |||||||||
| AβpSer8 | 0.00 | 0 (0) | 0 (0) | |||||||||
| symAD2 soluble fraction | Aβ | 83.33 | 6 | 0.266 (0.238) | 66.7 (40.4) | 0.017 | 4 | 4 | 10.88 | 3 | 3 | 2 |
| AβN3PE | 33.33 | 0.032 (0.064) | 15 (33.5) | |||||||||
| AβpSer8 | 66.67 | 0.043 (0.061) | 46.7 (44.3) | |||||||||
| symAD2 dispersible fraction | Aβ | 100.00 | 6 | 0.882 (0.696) | 69.4 (39.1) | 0.136 | 4 | 4 | 10.88 | 3 | 3 | 2 |
| AβN3PE | 83.33 | 0.031 (0.028) | 37.5 (34.4) | |||||||||
| AβpSer8 | 83.33 | 0.003 (0.002) | 18.8 (14.2) | |||||||||
| symAD2 total supernatant fraction | Aβ | 83.33 | 6 | 0.486 (0.611) | 54.4 (45) | 0.039 | 4 | 4 | 10.88 | 3 | 3 | 2 |
| AβN3PE | 33.33 | 0.005 (0.009) | 18.1 (28.1) | |||||||||
| AβpSer8 | 50.00 | 0.019 (0.023) | 29.2 (39.4) | |||||||||
| Comparison of the dispersible fraction among lysates from different cases | ||||||||||||
| PBS | Aβ | 14.29 | 7 | 0.001 (0.003) | 1.6 (4.2) | NA | NA | NA | NA | NA | NA | |
| AβN3PE | 0.00 | 0 (0) | 0 (0) | |||||||||
| AβpSer8 | 0.00 | 0 (0) | 0 (0) | |||||||||
| nonAD10 | Aβ | 0.00 | 7 | 0 (0) | 0 (0) | 0.001 | 0 | 0 | 0 | 0 | 0 | 0 |
| AβN3PE | 0.00 | 0 (0) | 0 (0) | |||||||||
| AβpSer8 | 0.00 | 0 (0) | 0 (0) | |||||||||
| nonAD2 | Aβ | 33.33 | 6 | 0.016 (0.024) | 9.2 (14.3) | <0.001 | 0 | 1 | 0 | 0 | 0 | 0 |
| AβN3PE | 16.67 | 0.001 (0.002) | 3.3 (8.2) | |||||||||
| AβpSer8 | 0.00 | 0 (0) | 0 (0) | |||||||||
| p-preAD2 | Aβ | 50.00 | 6 | 0.021 (0.024) | 27.1 (19.7) | 0.009 | 1 | 1 | 0 | 0 | 2 | 0 |
| AβN3PE | 33.33 | 0.001 (0.001) | 8.3 (11.8) | |||||||||
| AβpSer8 | 0.00 | 0 (0) | 0 (0) | |||||||||
| p-preAD14 | Aβ | 100.00 | 7 | 0.23 (0.195) | 36.4 (27.9) | 0.031 | 2 | 2 | 1.54 | 2 | 3 | 2 |
| AβN3PE | 85.71 | 0.029 (0.029) | 24.2 (22.2) | |||||||||
| AβpSer8 | 71.43 | 0.025 (0.026) | 10.7 (8.6) | |||||||||
| p-preAD21 | Aβ | 100.00 | 6d | 2.767 (1.541) | 91.7 (18.6) | 0.018 | 5 | 2 | 5.53 | 2 | 2 | 2 |
| AβN3PE | 83.33 | 0.017 (0.012) | 61.7 (32.6) | |||||||||
| AβpSer8 | 33.33 | 0.001 (0.002) | 15 (20.7) | |||||||||
| symAD2 | Aβ | 100.00 | 6 | 0.882 (0.696) | 69.4 (39.1) | 0.136 | 4 | 4 | 10.88 | 3 | 3 | 2 |
| AβN3PE | 83.33 | 0.031 (0.028) | 37.5 (34.4) | |||||||||
| AβpSer8 | 83.33 | 0.003 (0.002) | 18.8 (14.2) | |||||||||
n = number of animals treated for each condition. Values in bold highlight a positive percentage >76%. Note that Case p-preAD21 is exceptional since this case already showed the topographical distribution of Aβ phase 5 whereas AβpSer8 could not be detected within the plaques by immunohistochemistry. We used this case here because it allowed us to extract substantial amounts of Aβ in B-Aβ plaque stage 2. NA = not applicable.
Values presented as % (positive n/total n).
Values presented as % (±SD).
Values presented as mean (±SD).
One mouse from this group received the injection of dispersible fraction from Case p-preAD21 in the right hippocampus.